| Literature DB >> 29348994 |
Rosaria Di Lorenzo1, Jessica Pedretti2, Letizia Grossi1, Benedetta Cuoghi3, Cinzia Varni3, Giulia Landi4, Ludovica Spattini4, Chiara Visentini4, Paola Ferri5, Francesca Carubbi6.
Abstract
Weight gain and related metabolic syndrome (MS) are major current issues in public health. MS consists of abdominal fat, atherogenic dyslipidemia, hypertension, hyperglycemia, insulin resistance, pro-inflammatory and pro-thrombotic state, and accounts for both cardiovascular diseases and type II diabetes mellitus risk factors. Patients affected by psychiatric illness present a prevalence of 35-40% of MS. Many studies have shown that Mediterranean diet is associated with the reduction of mortality due to cardiovascular and malignant diseases, potentially preventing both obesity and type II diabetes mellitus. Our pilot study explores the effects of a 12-month healthy lifestyle program (Mediterranean diet and mild physical activity) on metabolic and anthropometric parameters of patients affected by chronic psychiatric disorders who live in a psychiatric community facility. A Mediterranean diet was provided by a senior nutritional clinician and adapted by two dieticians, according to the needs and preferences of the community population. Concomitantly, a program of moderate physical activity, consisting in 30-min walks on level ground 4 days a week, and psycho-educational group sessions with educational and therapeutic purposes were implemented. The metabolic and anthropometric parameters of our patients improved after both 6 (T6) and 12 (T12) months. Body Max Index was statistically significantly reduced at T6 and T12, with patients perceiving good quality of life. These positive outcomes suggest that a low-cost healthy lifestyle program can produce good adherence and feasibility even among patients with chronic psychiatric diseases, reducing their risk for MS, cardiovascular diseases and other complications.Entities:
Keywords: Antipsychotic drugs; Chronic psychiatric disorders; Mediterranean diet and mild physical activity; Rehabilitative community; Weight gain and metabolic syndrome
Year: 2017 PMID: 29348994 PMCID: PMC5767559 DOI: 10.1016/j.pmedr.2017.12.013
Source DB: PubMed Journal: Prev Med Rep ISSN: 2211-3355
Demographic and clinical characteristic of our Patients at T0 (n = 19).
| Demographic and clinical characteristics of our population | |
|---|---|
| Years | 66 ± 13.65 |
| Italians | 19 (100%) |
| Males | 8 (42%) |
| Females | 11 (58%) |
| Intermediate school | 15 (79%) |
| High School | 3 (16%) |
| Degree | 1(5%) |
| Single | 19 (100%) |
| Schizophrenic Disorders | 9 (47%) |
| Personality Disorders | 4 (21%) |
| Bipolar Disorders | 3 (16%) |
| Mental Retardation | 3 (16%) |
| Substance Abuse | 3 (16%) |
| Mental Retardation | 3 (16%) |
| Patients affected by an organic disease | 17 (89%) |
| Metabolic Syndrome | 10 (53%) |
| Anaemia | 3 (16%) |
| Chronic obstructive pulmonary disease (COPD) | 3 (16%) |
| Cholethiasis | 3 (16%) |
| Arthrosis | 3 (16%) |
| Parkinson syndrome and epilepsy | 3 (16%) |
| Cancer | 2 (10%) |
| Patients > 10 years for all patients | 19 (100%) |
| Patients with politherapy | 19 (100%) |
| typical antipsychotics | 68% |
| atypical antipsychotics | 74% |
| mood stabilizers | 53% |
| benzodiazepines | 74% |
| antidepressants | 5% |
| Patients treated with other drugs | 16 (84%) |
| antihypertensives | (31%) |
| anti-ulcerans | (31%) |
| hypolipids | (25%) |
| antidiabetics | (6%) |
| Patients | 6 (32%) |
Metabolic, anthropometric and cardiovascular parameters and scales scores of our Patients at T0, T6 and T12.
| Variables | T0 | T6 | T12 | Statistical test |
|---|---|---|---|---|
| BMI, m ± SD | 29.14 ± 7.03 | 27.75 ± 6.47* | 26.69 ± 6.72** | *vs BMI at T0 of 15 patients: |
| Waist circumference (cm), m ± SD | 105.93 ± 13.74 | 104.66 ± 15.24 | 105 ± 12.14 | |
| Glucose mg/dl, m ± SD | 78.26 ± 26 | 84 ± 24.96 | 82 ± 18.12 | |
| Homocysteine umoli/l, m ± SD | 16.01 ± 5.34 | 14.70 ± 6.95 | 14.90 ± 8.79 | |
| Total cholesterol mg/dl, m ± SD | 203.33 ± 47.92 | 209.8 ± 44.96 | 190.27 ± 56.04 | |
| HDL cholesterol mg/dl, | 51.06 ± 11.53 | 50.4 ± 14.69 | 54.91 ± 11.77 | |
| Triglycerides mg/dl, m ± SD | 141.26 ± 58.51 | 144.2 ± 61.06 | 114.73 ± 58.49 | |
| TSH | 1.89 ± 0 0.71 | 1.91 ± 0.73 | 1.65 ± 0.56 | |
| Uric acid | 5.23 ± 1.05 | 5.12 ± 0.95 | – | |
| Heart rate, m ± SD | 85.87 ± 16.64 | 83.93 ± 12.02 | 87.64 ± 10.84 | |
| Systolic blood pressure | 119 ± 8.06 | 121.67 ± 8.38 | 115.83 ± 10.17 | |
| ECG (QTc, m ± SD) | 0.422 ± 0.007 | 0.417 ± 0.02 | 0.412 ± 0.03 | |
| EQ-5D, m ± SD | – | 80.41 ± 16.30 | 75.33 ± 17.44 | |
| GAF | 32.55 ± 9.85 | 33.86 ± 12.66 | – | |
| BPRS | 23.53 ± 9.24 | 23 ± 8.75 | – |